A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

NCT06772532 · Completed

Last updated 2026-05-28

This study tests how three different versions of the drug survodutide are absorbed in the body when given to healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2025-02 · est. completion 2025-06

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06772532 ↗

Description as written by the study sponsor.

The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.

Treatments tested

BI 456906 - Formulation A also known as Survodutide Combination Product

Formulation A
BI 456906 - Formulation B also known as Survodutide Drug

Formulation B
BI 456906 - Formulation C also known as Survodutide Drug

Formulation C

Main thing measured	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06772532 ↗